Success or failure of blinding in randomized controlled trials
- PMID: 31670394
- DOI: 10.1111/dmcn.14388
Success or failure of blinding in randomized controlled trials
Comment on
-
Botulinum neurotoxin A, blinding, and bias.Dev Med Child Neurol. 2020 Feb;62(2):259. doi: 10.1111/dmcn.14297. Epub 2019 Jun 21. Dev Med Child Neurol. 2020. PMID: 31225641 No abstract available.
-
Blinding and bias in randomized controlled trials: when to measure the effectiveness of blinding.Dev Med Child Neurol. 2020 Feb;62(2):260. doi: 10.1111/dmcn.14369. Epub 2019 Sep 30. Dev Med Child Neurol. 2020. PMID: 31571206 No abstract available.
References
REFERENCES
-
- Kolahi J, Bang H, Park J. Towards a proposal for assessment of blinding success in clinical trials: up-to-date review. Community Dent Oral Epidemiol 2009; 37: 477-84.
-
- Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo-controlled trials. BMJ 2004; 328: 432.
-
- Sackett DL. Turning a blind eye: why we don't test for blindness at the end of our trials. BMJ 2004; 328: 1136.
-
- Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012; 10: 28-55.
-
- Hastings-Ison T, Graham K. Botulinum neurotoxin A, blinding, and bias. Dev Med Child Neurol 2020; 62: 259.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical